BiochemistryACS Infectious DiseasesPeer-reviewed
Contributions of hyperactive mutations in Mpro from SARS-CoV-2 to drug resistance
Julia M. Flynn, Sarah N. Zvornicanin, Tenzin Tsepal…·Daniel N. A. Bolon
This study identifies hyperactive mutations in SARS-CoV-2 Mpro that increase enzyme activity and contribute to drug resistance, finding them more prevalent than binding-reducing mutations.
23 citationstop 2%